Thus, a pronounced additive effect on prognosis of pT1+2 ccRCC patients, i.e. patients with an assumed lower risk of cancer-related death, was identified when combining uPA and uPAR antigen levels in tumour tissue. Here, PLAUR is linked to nonpapillary renal cell carcinoma.